What are the treatment options for laryngeal carcinoma?

Treatment of Laryngeal Carcinoma

All patients with T1-T2 laryngeal cancer should be treated with intent to preserve the larynx using either radiation therapy or larynx-preserving surgery, both offering equivalent survival outcomes; for T3-T4a disease, concurrent chemoradiotherapy (70 Gy with cisplatin 100 mg/m² on days 1,22,43) is the standard organ-preservation approach, while total laryngectomy is reserved for nonfunctional larynx, cartilage penetration into soft tissues, or salvage after failed preservation attempts. 1

Early-Stage Disease (T1-T2)

Treatment Modality Selection

• Radiation therapy and transoral laser microsurgery provide equivalent oncologic outcomes and should be the primary treatment options for T1-T2 glottic and supraglottic carcinomas. 1, 2
• Single-modality treatment is mandatory—combining surgery with radiation compromises functional outcomes and should be avoided unless salvage is required. 1
• Total laryngectomy is reserved exclusively for salvage of local recurrences that cannot be managed with additional partial surgery. 1

Radiation Therapy Protocol

• Deliver 70 Gy using intensity-modulated radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT) to the primary tumor. 3, 4
• For clinically node-negative disease, elective treatment to bilateral neck levels II-IV is recommended due to the 23-24% risk of occult cervical metastasis. 3, 5, 2

Surgical Approach

• Transoral laser microsurgery or transoral robotic surgery with wide local excision achieving ≥5 mm margins. 1, 2
• Elective ipsilateral selective neck dissection (levels I-III) is mandatory even in clinically node-negative patients to address occult metastasis. 3

Critical Selection Factors

• Vocal cord mobility, baseline voice and swallowing function (assessed by speech-language pathology), patient comorbidities, and local surgical expertise determine optimal modality. 1
• Pre-treatment comprehensive assessment of voice and swallowing function is required for all patients to guide treatment selection and establish baseline for post-treatment comparison. 1

Locally Advanced Disease (T3-T4a)

Standard Treatment Options

Concurrent chemoradiotherapy and primary surgery followed by adjuvant therapy provide equivalent survival outcomes—the choice depends on resectability, anticipated functional outcomes, and patient factors. 1, 4, 2

Concurrent Chemoradiotherapy (Organ Preservation)

• Standard regimen: 70 Gy IMRT/VMAT with cisplatin 100 mg/m² IV on days 1,22, and 43. 1, 4, 2
• Bilateral neck levels II-V must be treated in node-positive disease; levels II-IV bilaterally for clinically node-negative disease. 2
• For cisplatin-ineligible patients, acceptable alternatives include cetuximab concurrent with radiotherapy, carboplatin plus 5-fluorouracil, or hyperfractionated/accelerated radiotherapy alone. 1, 4, 6

Post-Treatment Neck Management

• Routine neck dissection is not required if 12-week post-treatment FDG-PET/CT shows no metabolic activity and normal-sized nodes. 4, 2
• Neck dissection is reserved for patients with partial response or increased uptake on PET-CT. 2

Surgical Management

• Primary en bloc resection (including involved bone or soft tissue) followed by comprehensive neck dissection is the alternative to chemoradiotherapy. 1, 3, 4
• Transoral robotic surgery or open partial laryngectomy may be appropriate in selected cases when complete resection is achievable and appropriate surgical expertise and multidisciplinary rehabilitation services are available. 4, 2

Adjuvant Therapy Indications and Timing

• Post-operative concurrent chemoradiotherapy (66 Gy with cisplatin 100 mg/m² on days 1,22,43) is mandatory for positive surgical margins (R1) or extracapsular nodal extension. 3, 4
• Post-operative radiotherapy alone (60-64 Gy) is indicated for pT3-T4 disease, perineural invasion, lymphovascular invasion, or >1 involved lymph node without extracapsular extension. 3, 4
• Initiate adjuvant therapy within 6-7 weeks after surgery and complete the entire sequence within 11 weeks—delays beyond this compromise locoregional control. 3, 4

Contraindications to Organ Preservation

Patients with nonfunctional larynx (extensive T3 or T4a) or tumor penetration through cartilage into surrounding soft tissues are poor candidates for larynx preservation—primary total laryngectomy is recommended. 1

• Cartilage invasion through to soft tissues of the neck mandates total laryngectomy, as concurrent chemoradiotherapy yields inferior outcomes in this setting. 2

Recurrent and Metastatic Disease

First-Line Systemic Therapy

• For PD-L1-positive tumors (CPS ≥1): pembrolizumab combined with platinum-based chemotherapy and 5-fluorouracil when rapid tumor shrinkage is needed, or pembrolizumab monotherapy when swift response is not required. 3, 5, 4
• For PD-L1-negative disease: the EXTREME regimen (platinum + 5-fluorouracil + cetuximab) remains the standard first-line therapy. 3, 5, 4

Second-Line Therapy

• Nivolumab is the preferred second-line agent after platinum failure, providing median overall survival of 7.5 months versus 5.1 months with standard chemotherapy. 5, 4
• Alternative options include cetuximab (median OS 5-6 months) or taxane-based regimens, though the latter lack randomized trial support. 3, 5

Salvage Surgery

• Isolated locoregional recurrence should be evaluated at a tertiary center for possible salvage total laryngectomy or re-irradiation in highly selected cases. 5

Essential Multidisciplinary Requirements

Mandatory Team Composition

• All treatment decisions must be reviewed by a multidisciplinary tumor board comprising head-and-neck surgeons, radiation oncologists, medical oncologists, pathologists, radiologists, speech-language pathologists, dietitians, and psychologists. 1, 3, 4
• Management should be performed at high-volume centers with dedicated head-and-neck oncology expertise to optimize outcomes. 3, 5, 4

Pre-Treatment Assessment

• Comprehensive evaluation of voice and swallowing function by speech-language pathology is mandatory for all patients to guide treatment selection and establish baseline. 1
• Assessment must include vocal cord mobility, voice requirements, and counseling regarding potential effects on quality of life. 1

Critical Pitfalls to Avoid

Smoking Cessation

• Continued cigarette smoking is associated with worse outcomes after therapy—patients must be counseled to abstain from smoking immediately after diagnosis and enrolled in smoking cessation programs throughout and following treatment. 1

Treatment Timing

• Do not delay adjuvant therapy beyond 6-7 weeks post-surgery or extend total treatment duration beyond 11 weeks, as this compromises locoregional control. 3, 4

Inappropriate Combined Modality

• Avoid combining surgery with radiotherapy for early-stage disease, as functional outcomes are compromised by combined-modality therapy when single modality is curative. 1

Surveillance

• Close surveillance is essential because approximately 50% of patients with locally advanced disease experience recurrence, most within the first two years—follow-up should include head-and-neck examination with flexible endoscopy every 1-3 months for the first two years. 5, 4